

AWARD NUMBER: W81XWH-21-1-0732

TITLE: Implementation of Kidney Cancer-Specific Training for Clinical Research Nurses

PRINCIPAL INVESTIGATOR: Lauren Evans

**CONTRACTING ORGANIZATION: Sloan Kettering Institute for Cancer Research
New York, NY**

REPORT DATE: October 2022

TYPE OF REPORT: Annual

**PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012**

DISTRIBUTION STATEMENT: Approved for Public Release, Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2022	2. REPORT TYPE Annual	3. DATES COVERED 30Sep2021-29Sep2022
4. TITLE AND SUBTITLE Implementation of Kidney Cancer-Specific Training for Clinical Research Nurses		5a. CONTRACT NUMBER W81XWH-21-1-0732
		5b. GRANT NUMBER
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) Lauren Evans, Patricia Fischer, Susanne Gornell, Chung-Han Lee Robert Motzer, Robert Goodman, Alisa Ritea, Cindy Puzio		5d. PROJECT NUMBER
		5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Sloan Kettering Institute of Cancer Research 1275 York Ave New York, NY 10065		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release, Distribution Unlimited		
13. SUPPLEMENTARY NOTES		
14. ABSTRACT During the review period, investigators and mentors are credited in initiating a renal cell cancer clinical research nurse-specific training and orientation program for three clinical research nurse trainees. We have also mentored the clinical research nurse trainees in the beginning stages of the research project.		

15. SUBJECT TERMS Clinical trial nursing, Training, Telemedicine					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified	Unclassified	20	USAMRDC
					19b. TELEPHONE NUMBER <i>(include area code)</i>

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	6
2. Keywords	6
3. Accomplishments	6
4. Impact	9
5. Changes/Problems	10
6. Products	12
7. Participants & Other Collaborating Organizations	14
8. Special Reporting Requirements	17
9. Appendices	17

1. INTRODUCTION:

Clinical trial development has been critical for improving the outcomes of patients with kidney cancer, with the approval of 13 new treatments in the last 15 years. With proper oversight, clinical trials provide patients safe, early access to new medications that are promising. However, access to these novel treatments can be limited by the availability of expertise. Clinical research nurses (CRNs) are critical members of the patient's medical team that ensure that new medications can be delivered ethically, safely, and effectively. We hypothesize that having CRNs that are specialized in kidney cancer will improve the safety and tolerability of patients treated on clinical trials by improving the management of side effects and making sure patients adhere to the schedule and rules of the clinical trial.

To improve the access of disease-specific CRNs, we propose a project with two specific aims:

Specific Aim 1: Establish a kidney cancer-specific CRN training program

Specific Aim 2: Perform a pilot project to study the safety and quality of care when integrating telemedicine into clinical trial nursing

2. KEYWORDS:

Clinical trial nursing, Training, Telemedicine

3. ACCOMPLISHMENTS:

What were the major goals of the project?

Specific Aim 1: To establish a kidney cancer-specific fellowship program for CRNs

- Major Task 1: Train and orient CRN trainees who have limited experience in management of kidney cancer patients in research setting
- Major Task 2: Educate CRN trainees on kidney cancer pathophysiology, disease and symptom management, clinical research nursing practice, nursing research, and clinical trial operations

Specific Aim 2: To conduct a pilot research project providing research training experience to CRNs

- Major Task 1: Train and orient CRN trainees and CRA
- Major Task 2: Collection of safety and protocol compliance data from target populations

- Major Task 3: To compare healthcare utilization via outpatient and inpatient points of care before and after telemedicine adoption
- Major Task 4: To determine safety and protocol compliance as defined by rates of SAEs, rates of grade 3 and 4 toxicity, and rates of protocol deviations before and after telemedicine adoption
- Major Task 5: To compare patient and provider perceptions of telemedicine as a contributor to encountered SAEs

What was accomplished under these goals?

Specific Aim 1:

- *Major Task 1:*
 - *Completed: Subtasks 1 – 11*
 - *Ongoing: Subtask 12 – 18 will be delayed by 6 months to be completed in months 12-18*
- *Major Task 2:*
 - *Completed: Subtask 2, 3, 5, 6, 8, 9*
 - *Ongoing: Subtask 1, 4, 7 are ongoing as per schedule*

Specific Aim 2:

- *Major Task 1:*
 - *Completed: Subtask 1-3*
- *Major Task 2:*
 - *Completed: Subtask 1, 2, 3*
 - *Ongoing: Subtask 4 (ongoing patient accrual as per timeline), Subtask 5 (ongoing data collection as per timeline)*
- *Major Task 3:*
 - *Nothing to report*
- *Major Task 4:*
 - *Completed: Subtask 1*
- *Major Task 5:*
 - *Completed: Subtask 1 and 2*
 - *Ongoing: Subtask 3 as per schedule*

What opportunities for training and professional development has the project provided?

Include participation in conferences, workshops, and seminars not listed under major activities.

CTN trainee 1, 2, 3 attending didactic lectures

CTN trainee 2, completed one on one mentoring

CTN trainee 1 completed participation in research project, trainee 2 has ongoing participation in research project,

CTN trainee 1, 2, 3 participated in journal club and weekly clinical trial research meetings.

How were the results disseminated to communities of interest?

Nothing to report

What do you plan to do during the next reporting period to accomplish the goals?

.

Research for specific aim 2 will be published in a manuscript describing the perceptions of telemedicine in clinical trial management

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

Nothing to report

What was the impact on other disciplines?

Nothing to report

What was the impact on technology transfer?

Nothing to report

What was the impact on society beyond science and technology?

Nothing to report

5. CHANGES/PROBLEMS:

Nothing to report

Actual or anticipated problems or delays and actions or plans to resolve them

Nothing to report

Changes that had a significant impact on expenditures

Nothing to report

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Significant changes in use or care of human subjects

Nothing to report

Significant changes in use of biohazards and/or select agents

Nothing to report

6. PRODUCTS:

- **Publications, conference papers, and presentations**

Journal publications.

Nothing to report

Books or other non-periodical, one-time publications.

Nothing to report

Other publications, conference papers and presentations.

Nothing to report

- **Website(s) or other Internet site(s)**

Nothing to report

- **Technologies or techniques**

Nothing to report

- **Inventions, patent applications, and/or licenses**

Nothing to report

- **Other Products**

Nothing to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

Name: Lauren Evans

Role: PI

Nearest person month worked: 1.80 cal months

Name: Patricia Fischer

Role: Facilitator/Mentor

Nearest person month worked: 1.20 cal months

Name: Susanne Gornell

Role: Facilitator/Mentor

Nearest person month worked: 0.00 cal months / per the application

Name: Robert Goodman

Role: CRN Trainee

Nearest person month worked: 1.20 cal months / per the application

No additional funding support is available for the trainee

Name: Alisa Ritea

Role: CRN Trainee

Nearest person month worked: 1.20 cal months / per the application

No additional funding support is available for the trainee

Name: Cindy Puzio

Role: CRN Trainee

Nearest person month worked: 1.20 cal months / per the application

No additional funding support is available for the trainee

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Please see updated support documentation

What other organizations were involved as partners?

Nothing to report

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS:

QUAD CHARTS:

9. APPENDICES:

Previous/Current/Pending Support: Lauren Evans

Current

*Title: *Implementation of Kidney Cancer Specific Training for Clinical Research Nurses*

*Major Goals/Aims: To establish a kidney cancer-specific fellowship program for CRNs
2. To conduct a pilot research project providing research training experience to CRNs.

*Status of Support: Active

Project Number: W81XWH2110732

Source of Support: Congressionally Directed Medical Research Programs

Primary Place of Performance: Sloan Kettering Institute For Cancer Research

Project/Proposal Start and End Date (MM/YYYY): 9/30/2021 - 9/29/2023

*Total Award Amount (including Indirect Costs):

Role: Principal Investigator

Name of Contracting/Grants Officer:: Medha Darshan, M.S., MAT, Science Officer | Grants Officer Representative |US Army Medical Research and Development Command (USAMRDC), medha.s.darshan.civ@health.mil,

Person Months (Calendar/Academic/Summer) per budget period.

Year (YYYY) Person Months (##.##)

1. 2022 1.80 calendar
2. 2023 1.80 calendar

OVERLAP: None

Completed

None

Previous/Current/Pending Support
Fischer, Patricia

Previous Support

None.

Current Support

KC200301P1 (PI: Evans) 09/30/2021 – 09/29/2023 1.20
calendar

Congressionally Directed Medical Research

Implementation of Kidney Cancer-Specific Training for Clinical Research Nurses

We propose the development of a formal RCC CRN fellowship program to provide clinical training alongside RCC-specific mentorship, didactic lectures, and clinical and translational research training. CRN Trainees will be paired one-to-one with CRN and Physician Mentors during the fellowship, which will contain a clinical orientation phase, an education phase, and a research phase.

Aim 1: To establish a kidney cancer-specific fellowship program for CRNs

Aim 2: To conduct a pilot research project providing research training experience to CRNs

Aim 2a: To compare healthcare utilization via outpatient and inpatient points of care before and after telemedicine adoption

Aim 2b: To determine safety and protocol compliance, defined as rates of SAEs, rates of grade 3 and 4 toxicity, and rates of protocol deviations before and after telemedicine adoption.

Aim 2c: To compare patient and provider perceptions of telemedicine as a contributor to encountered SAEs.

Role: Facilitator/Mentor

Overlap: None.

Name of Contracting/Grants Officer: Joshua D. McKean, Grants Officer

Email: joshua.d.mckean3.civ@mail.mil |

Address: Department of the Army, US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014

Pending Support:

None

Previous/Current/Pending Support
Gornell, Suzanne

Previous Support

Title: Adaptive Immune Response to Nivolumab in Patients with Advanced Renal Cell Carcinoma

Role: Research Nurse

Sponsoring Agency: American Cancer Society

Effort: 3.0 CM

Funding Amount:

Performance Period: 1/1/2017–12/31/2020 (NCE)

Name of Grants Officer at Sponsoring Agency: American Cancer Society Extramural Research Department

Contact Information for Grants Officer: grants@cancer.org

Goals/Specific Aims: The goal of this study is to assess the safety and feasibility of neoadjuvant nivolumab administration in patients with resectable, high-risk, nonmetastatic renal cell carcinoma.

Overlap: None.

Current Support

KC200301P1 (PI: Evans)

09/30/2021 – 09/29/2023

0.00

calendar*

Congressionally Directed Medical Research

Implementation of Kidney Cancer-Specific Training for Clinical Research Nurses

We propose the development of a formal RCC CRN fellowship program to provide clinical training alongside RCC-specific mentorship, didactic lectures, and clinical and translational research training. CRN Trainees will be paired one-to-one with CRN and Physician Mentors during the fellowship, which will contain a clinical orientation phase, an education phase, and a research phase.

*No measurable effort/no salary support requested

Aim 1: To establish a kidney cancer-specific fellowship program for CRNs

Aim 2: To conduct a pilot research project providing research training experience to CRNs

Aim 2a: To compare healthcare utilization via outpatient and inpatient points of care before and after telemedicine adoption

Aim 2b: To determine safety and protocol compliance, defined as rates of SAEs, rates of grade 3 and 4 toxicity, and rates of protocol deviations before and after telemedicine adoption.

Aim 2c: To compare patient and provider perceptions of telemedicine as a contributor to encountered SAEs.

Role: Mentor

Overlap: None.

Name of Contracting/Grants Officer: Joshua D. McKean, Grants Officer

Email: joshua.d.mckean3.civ@mail.mil |

Address: Department of the Army, US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014

Pending Support:

None